Business Description
Replimune Group Inc
NAICS : 325412
SIC : 2834
ISIN : US76029N1063
Total Employee Number:
479Description
Replimune Group Inc is a clinical-stage biotechnology company committed to applying its expertise in the field of oncolytic immunotherapy to transform the lives of cancer patients through novel oncolytic immunotherapies. Its proprietary oncolytic immunotherapy product candidates are designed and intended to maximally activate the immune system against cancer. Oncolytic immunotherapy is an emerging drug class. The proprietary RPx platform is based on a novel, engineered strain of herpes simplex virus 1, or HSV-1, backbone with payloads added that are intended to maximize immunogenic cell death and the induction of a systemic anti-tumor immune response. It operates in single segment of developing oncolytic immunotherapies for the treatment of cancer.
Financial Strength
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 2.41 | |||||
Equity-to-Asset | 0.5 | |||||
Debt-to-Equity | 0.67 | |||||
Debt-to-EBITDA | -0.37 | |||||
Piotroski F-Score | 1/9 | |||||
WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year EBITDA Growth Rate | -4.2 | |||||
3-Year EPS without NRI Growth Rate | -3.7 | |||||
3-Year FCF Growth Rate | -11 | |||||
3-Year Book Growth Rate | -41 | |||||
Future 3-5Y EPS without NRI Growth Rate Estimate Industry Rank | 45.69 |
Momentum Rank
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 40.87 | |||||
9-Day RSI | 56.63 | |||||
14-Day RSI | 62.22 | |||||
3-1 Month Momentum % | 77.94 | |||||
6-1 Month Momentum % | 5.48 | |||||
12-1 Month Momentum % | -21.36 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 4.79 | |||||
Quick Ratio | 4.79 | |||||
Cash Ratio | 4.62 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -13.4 | |||||
Shareholder Yield % | -4.31 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
ROE % | -112.72 | |||||
ROA % | -75.6 | |||||
ROIC % | -405.46 | |||||
3-Year ROIIC % | -2080.51 | |||||
ROC (Joel Greenblatt) % | -596.25 | |||||
ROCE % | -85.22 | |||||
Moat Score | 5 | |||||
Tariff Resilience Score | 8 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PB Ratio | 5.47 | |||||
Price-to-Tangible-Book | 5.47 | |||||
EV-to-EBIT | -2.5 | |||||
EV-to-EBITDA | -2.53 | |||||
EV-to-Forward-Revenue | 4.49 | |||||
EV-to-FCF | -2.69 | |||||
| Price-to-Net-Current-Asset-Value | 8.08 | |||||
| Price-to-Net-Cash | 8.87 | |||||
Earnings Yield (Greenblatt) % | -40 | |||||
FCF Yield % | -30.85 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:REPL
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Replimune Group Inc Executives
DetailsGF Valueâ„¢
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | |||
| EPS (TTM) ($) | -3.38 | ||
| Beta | 0.0573 | ||
| 3-Year Sharpe Ratio | 0.34 | ||
| 3-Year Sortino Ratio | 1.01 | ||
| Volatility % | 289.71 | ||
| 14-Day RSI | 62.22 | ||
| 14-Day ATR ($) | 0.842294 | ||
| 20-Day SMA ($) | 10.66675 | ||
| 12-1 Month Momentum % | -21.36 | ||
| 52-Week Range ($) | 1.5 - 13.24 | ||
| Shares Outstanding (Mil) | 83.95 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 1 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Replimune Group Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Replimune Group Inc Stock Events
| Event | Date | Price ($) | ||
|---|---|---|---|---|
| Second quarter earnings results for 2027 | 2026-11-06 | In 118 days | ||
| General meeting for 2026 | 2026-09-03 11:30 | In 55 days | ||
| First quarter earnings results for 2027 | 2026-08-07 | In 27 days | ||
| Annual report for 2026 | 2026-06-29 | 11.63 (+13.77%) | ||
| Fourth quarter earnings results for 2026 | 2026-06-29 | 11.63 (+13.77%) | ||
| Third quarter earnings results for 2026 | 2026-02-03 | 6.98 (+0.36%) | ||
| 44(th) Annual J.P. Morgan Healthcare Conference | 2026-01-14 13:30 | 8.04 (-0.12%) | ||
| Second quarter earnings results for 2026 | 2025-11-06 | 8.58 (-3.60%) | ||
| General meeting for 2025 | 2025-09-03 11:30 | 5.90 (+6.88%) | ||
| First quarter earnings results for 2026 | 2025-08-07 | 5.50 (-12.42%) |
Show
Entries
Replimune Group Inc Frequently Asked Questions
What is Replimune Group Inc(REPL)'s stock price today?
The current price of REPL is $11.00. The 52 week high of REPL is $13.24 and 52 week low is $1.50.
When is next earnings date of Replimune Group Inc(REPL)?
The next earnings date of Replimune Group Inc(REPL) is 2026-08-07 Est..
Does Replimune Group Inc(REPL) pay dividends? If so, how much?
Replimune Group Inc(REPL) does not pay dividend.
Guru Commentaries on NAS:REPL
No articles.
Press Release
Articles on Replimune Group Inc
Headlines
See More- 1
Jul 01, 2026
Four stock-moving events to watch as FDA revives AdComs
Seeking Alpha • 12:51pm
Jun 26, 2026
Capricor falls as FDA sets up AdCom meeting to review Duchenne therapy
Seeking Alpha • 8:59am
Jun 17, 2026
Regenxbio, Replimune among gainers after FDA U-turn on UniQure
Seeking Alpha • 1:35pm
- 1
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers